For LDL-C reduction in patients with hypercholesterolemia along with diet and exercise.1
Be confident your patients have received their dose with HCP-administered LEQVIO—the only twice-yearly* LDL-C–lowering therapy.1
Are your patients ready to start LEQVIO? Find coverage in your area and fill out the Patient Start Form to begin.
*After 2 initial doses.
“When I saw the LEQVIO commercial…2 doses a year, I thought man, that’s what I need to be on.”
Linda S., LEQVIO patient compensated for her time.
Individual results may vary.
After 2 initial doses.
†An event is defined as acute coronary syndrome (unstable angina, STEMl, or NSTEMI). Patients were screened within 5 weeks from their coronary event.2
HCP, health care provider; LDL-C, low-density lipoprotein cholesterol; mAbs, monoclonal antibodies; NSTEMI, non–ST-elevation myocardial infarction; PCSK9, proprotein convertase subtilisin/kexin type 9; STEMI, ST-elevation myocardial infarction.
HCP, health care provider; LDL-C, low-density lipoprotein cholesterol; mAbs, monoclonal antibodies; NSTEMI, non–ST-elevation myocardial infarction; PCSK9, proprotein convertase subtilisin/kexin type 9; STEMI, ST-elevation myocardial infarction.